DEF 14A: MariMed Inc. Announces 2024 Annual Meeting of Stockholders

MariMed Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 6, 2024, to elect directors and approve the appointment of independent auditors.

Summary

• MariMed Inc. will hold its Annual Meeting of Stockholders on June 6, 2024, at 9:30 a.m. Eastern Time at the Courtyard by Marriott Boston Dedham/Westwood.
• Stockholders of record as of April 15, 2024, are entitled to vote.
• The meeting will address the election of five directors, the advisory approval of M&K CPAs PLLC as the company's independent auditors for the fiscal year ending December 31, 2024, and any other business that may properly come before the meeting.
• As of the record date, there were 379,389,444 common shares, 4,908,333 Series B preferred shares, and 1,155,274 Series C preferred shares outstanding.
• Each common share and Series B preferred share is entitled to one vote.
• The board recommends voting for the election of each director nominee and for the approval of the appointment of M&K as independent accountants.
• During 2023, the non-employee director annual retainer increased from $25,000 to $40,000, and the annual equity grant increased to 75,000 restricted stock units (RSUs).
• The CEO's base salary is $375,000, effective March 1, 2023, with a target bonus opportunity equal to 60% of his then-applicable annual base salary and a maximum bonus opportunity equal to 120% of his then-applicable annual base salary.
• The COO's base salary is $325,000, effective March 1, 2023, with a target bonus opportunity equal to 60% of his then-applicable annual base salary and a maximum bonus opportunity equal to 120% of his then-applicable annual base salary.
• The company's corporate offices are leased from an entity in which the CEO has an investment interest, with expenses under this lease in the years ended December 31, 2023 and 2022 were approximately $272,000 and $156,000, respectively.
• Purchases from an entity owned by the family of the COO totaled $6.5 million and $4.8 million in the years ended December 31, 2023 and 2022, respectively.
• The aggregate royalties due to an entity owned by the COO and the CRO for the years ended December 31, 2023 and 2022 approximated $722,000 and $219,000, respectively.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral tone. The disclosure of related party transactions introduces a slight element of concern, but the overall sentiment is moderately positive due to the company's commitment to corporate governance and compliance.

Positives

• The Board is comprised of a majority of independent directors.
• The company has established Audit, Compensation, and Nominating and Governance Committees, each made up entirely of independent directors.
• The company has a Code of Ethics in place for its Board, executive officers, and employees.
• The Audit Committee pre-approves all audit and non-audit services before an accountant is engaged.

Negatives

• The company leases its corporate offices from an entity in which the CEO has an investment interest.
• The company procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the COO.
• The company pays royalties on the revenue generated from its Bettys Eddies product line to an entity owned by the COO and the CRO.
• One of the company's majority-owned subsidiaries paid distributions to the CEO, who owns a minority equity interest in such subsidiary.
• First State Compassion Center (FSCC), the cannabis-licensed client in Delaware that the company manages, paid fees to BKR Management Inc., a company partially owned by the CEO, related to the initial formation, licensing and establishment of FSCC's cannabis operations.

Risks

• The document mentions related party transactions, which could present potential conflicts of interest.
• The company's success depends on the performance and expertise of its executive officers and directors.
• Changes in laws and regulations related to the cannabis industry could impact the company's operations and financial performance.
• The company faces risks related to credit, liquidity, strategy, and operations.

Future Outlook

The document outlines the matters to be voted on at the Annual Meeting and provides information about the company's governance, executive compensation, and related party transactions. It does not contain specific forward-looking statements about the company's future financial performance or business prospects.

Management Comments

• Thank you for your continued support, interest and investment in MariMed.
• The Board evaluates its leadership structure and role in risk oversight on an ongoing basis and makes decisions on the basis of what it considers to be best for the Company at any given point in time.

Industry Context

As a cannabis company, MariMed operates in a rapidly evolving industry with increasing regulatory scrutiny and competition. The company's focus on corporate governance and compliance is essential for maintaining investor confidence and navigating the complex legal landscape.

Comparison to Industry Standards

• The director compensation structure, including retainers and equity grants, is generally in line with industry standards for publicly traded companies of similar size and stage.
• The related party transactions disclosed are not uncommon in the cannabis industry, where access to capital and resources can be limited, but they require careful oversight and management to avoid potential conflicts of interest.
• The company's commitment to independent board committees and a code of ethics reflects a growing emphasis on corporate governance best practices in the cannabis sector.

Management Changes

Corporate Governance

Related Party Transactions

• The company's corporate offices are leased from an entity in which the CEO has an investment interest.
• The company procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the COO.
• The company pays royalties on the revenue generated from its Bettys Eddies product line to an entity owned by the COO and the CRO.
• One of the company's majority-owned subsidiaries paid distributions to the CEO, who owns a minority equity interest in such subsidiary.
• First State Compassion Center (FSCC), the cannabis-licensed client in Delaware that the company manages, paid fees to BKR Management Inc., a company partially owned by the CEO, related to the initial formation, licensing and establishment of FSCC's cannabis operations.
• At December 31, 2023, the Company's mortgages with Bank of New England and DuQuoin State Bank were personally guaranteed by the CEO under a limited guaranty.

Stakeholder Impact

• Shareholders are asked to vote on the election of directors and the appointment of independent auditors.
• Executive officers and directors are subject to the company's insider trading policy.
• The company's Code of Ethics applies to its Board, executive officers, and employees.
• The company's related party transactions could impact stakeholders if not managed properly.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 6, 2024.
• The Audit Committee will continue to oversee the company's financial reporting process and relationship with its independent auditors.
• The Board will continue to evaluate its leadership structure and risk management practices.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Auditors, Executive Compensation, Related Party Transactions, Stockholders, MariMed Inc., Governance, Cannabis